News

Prescient Therapeutics building the platform for future cancer treatments

February 10, 2021

Prescient Therapeutics building the platform for future cancer treatments

Australian listed biotech company Prescient Therapeutics (ASX: PTX) is forging a path for other prospective cancer treatments, by developing a platform to improve the performance of CAR T drugs.

Australian listed biotech company Prescient Therapeutics (ASX: PTX) is forging a path for other prospective cancer treatments, by developing a platform to improve the performance of CAR T drugs.

And by focusing on the “targets and tools” CAR-T treatments rely on, Prescient CEO Steven Yatomi-Clarke said the company stands to benefit regardless of who wins the race to develop these life-saving drugs.

“We believe the people in the gold rush who make the money are those who sell the shovels,” he told Dr Nigel Finch in a recent webinar for Stockhead.

In this instance, Mr Yatomi-Clarke sought to work with industry leaders to create tools future generations of CAR T therapies can utilise to more effectively handle the challenges currently holding the sector back.

“[We looked to partner with] people who had the tools to really alleviate the bottlenecks that are presenting themselves early on in this amazing field, and that led us to the University of Pennsylvania, who pioneered CAR T.,’ he said.

“We have subsequently announced the arrival of OmniCAR, which is a next generation platform.”

CAR T therapies work by taking blood from a cancer patient and retraining their own immune cells to identify and fight cancerous cells, and while it has yielded positive results in certain cancers, this radical treatment comes with a number of challenges.

Specifically, current generation CAR T cells have limited ability to attack multiple targets on tumors at once, for doctors to fine-tune dosages to avoid them reaching toxic levels, or for the cells to be modified in response to mutating tumors.

Prescient’s OmniCAR platform addresses these challenges.

 

You can hear Mr Yatomi-Clarke’s discussion with Stockhead’s Dr Nigel Finch from 9 February below.

To stay up to date with the latest company news and announcements register your details on the investor centre.

 

Reach Markets have been engaged by PTX to assist with private investor management.

Sources:

 


General Advice Warning

Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG) including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.

Please click here to read our full warning.

Investor Briefing

Learn how data centres are shaping Australia's business growth

Leave a comment